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Background and aims: The objective of this investigation was to assess the effects of probiotic and se-
lenium co-supplementation on indicators of mental health and metabolic proﬁles in diabetic people with
coronary heart disease (CHD).
Methods: This randomized, double-blind, placebo-controlled trial was conducted among 54 diabetic
people with CHD. Patients were randomly allocated into two groups to receive either 200 mg/day sele-
nium plus 8  109 CFU/day probiotic (n ¼ 27) or placebo (n ¼ 27) for 12 weeks.
Results: Probiotic and selenium co-supplementation signiﬁcantly decreased Beck Depression Inventory
index (b 1.46; 95% CI, 2.61, 0.31; P ¼ 0.01) and Beck Anxiety Inventory index (b 1.23; 95%
CI, 2.33, 0.12; P ¼ 0.02) compared with the placebo. Consuming probiotic plus selenium lowered
fasting plasma glucose (b 10.80 mg/dL; 95% CI, 17.68, 3.92; P ¼ 0.003), serum insulin levels (b 3.42
mIU/mL; 95% CI, 4.93, 1.90; P < 0.001), insulin resistance (b 0.96; 95% CI, 1.45, 0.47; P < 0.001),
and enhanced insulin sensitivity (b 0.01; 95% CI, 0.007, 0.01; P < 0.001) compared with the placebo.
Additionally, co-supplementation reduced triglycerides (b 34.45 mg/dL; 95% CI, 56.18, 12.72;
P ¼ 0.003), VLDL- (b 6.89 mg/dL; 95% CI, 11.23, 2.54; P ¼ 0.003), total cholesterol (b 18.13 mg/dL;
95% CI, 23.42, 2.83; P ¼ 0.02) and high sensitivity C-reactive protein (b 1043.28 ng/mL; 95%
CI, 1929.67, 156.89; P ¼ 0.02), and increased nitric oxide (b 7.86 mmol/L; 95% CI, 5.63, 10.09; P < 0.001),
total antioxidant capacity (b 119.30 mmol/L; 95% CI, 63.04, 175.57; P < 0.001) and total glutathione (b
154.16 mmol/L; 95% CI, 82.57, 225.74; P < 0.001) compared with the placebo.
Conclusions: Probiotic and selenium co-supplementation to diabetic people with CHD improved in-
dicators of mental health and metabolic proﬁles.
Registered under Clinical Trials.gov Identiﬁer no. http://www.irct.ir: IRCT20170513033941N28.
© 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Type 2 diabetes mellitus (T2DM) and obesity are risk factors for
coronary heart disease (CHD) and stroke [1]. Diabetic patients
compared with nondiabetic people bear up to six-fold higher risk of
future CHD [2]. Various factors including obesity, insulin resistance,
dyslipidemia and hypertension in diabetic patients may affect
vascular risk [3]. Disorders related to mental health such asfor Clinical Nutrition and Metabol
et al., The effects of probiotic
nts with coronary heart dise
nu.2018.07.017depression, and T2DM and CHD occur together and this status can
cause a vicious circle [4]. Approximately, 30% of the people with
T2DM and/or CHD has subthreshold depression and higher than
40% of those will develop major depressive disorder within two
years [5]. Moreover, increased inﬂammatory markers and oxidative
damage play important roles in the progress of diabetes and
atherosclerosis [6].
It was reported that selenium levels were low in diabetic pa-
tients with peripheral artery disease [7]. In addition, the gut
microbiota plays an important function in host metabolism and has
been associated with metabolic disorders and mental health [8].
However, the beneﬁcial effects of only selenium or probioticism. All rights reserved.
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or CHD were previously reported, data on combined selenium and
probiotic supplementation on metabolic proﬁles in these patients
are limited. In two meta-analyses studies, the beneﬁcial effects of
selenium on inﬂammation and oxidative damage [9] and probiotic
on lipid proﬁles among people with CHD [10] were reported.
Combined selenium and probiotic administration may reduce
complications of people with T2DM and CHD by improving their
metabolic proﬁles and attenuating oxidative stress and inﬂamma-
tion. Nido et al. [11] demonstrated that selenium-enriched pro-
biotic than only selenium or probiotic improved metabolic proﬁles
in an animal study.
Both probiotics and selenium have antidiabetic, antioxidant and
anti-inﬂammatory effects, therefore we hypothesized that co-
administration of probiotic and selenium might beneﬁt diabetic
patients diagnosed with CHD. To address the hypotheses, this study
was aimed to determine the effects of probiotic and selenium co-
supplementation on mental health and metabolic status of dia-
betic patients with CHD.2. Methods
2.1. Trial design and participants
This study was a randomized, double-blinded, placebo-
controlled trial registered with Iranian Clinical Trials website
(http://www.irct.ir: IRCT20170513033941N28). Study participants
aged 45e85 years old had been diagnosed with both T2DM and
CHD. The criteria of the American Diabetes Association and Amer-
ican Heart Association were used to diagnose T2DM and 2- and 3-
vessel CHD, respectively. Study protocol was approved by the
research ethics committee of Kashan University of Medical Sciences
(KAUMS) and informed consent was signed by all participants. The
study was conducted from December 2017 through March 2018.
Participants reported selenium, probiotic and/or synbiotic con-
sumptionwithin the last 3 months, patients with thyroid disorders,
severe renal insufﬁciency and hepatic failure, and those experi-
encing an acute myocardial infarction and cardiac surgery within
the past 3 months were excluded from the study.2.2. Study procedures
Initially, study participants were stratiﬁed according to their age
and BMI. Then, they were randomly allocated into intervention
groups to receive either 200 mg/day selenium as selenium yeast
(Webber Naturals Company, Coquitlam, Canada) plus 8  109 CFU/
day probiotic (LactoCare®, Zisttakhmir Company, Tehran, Iran)
containing Lactobacillus acidophilus, Lactobacillus reuteri, Lactoba-
cillus fermentum and Biﬁdobacterium biﬁdum (2  109 CFU/g each)
or placebo (Barij Essence, Kashan, Iran) (n ¼ 27 each group) for 12
weeks. Computer-generated random numbers were used for
randomization. Randomization and allocationwere concealed from
both researchers and participants until the completion of ﬁnal
analyses. All process of randomization, enrollment, and partici-
pants' assignment into the intervention groups were conducted by
a trained nutritionist. Compliance rate was estimated by counting
the pills of placebo, selenium and probiotics in the returned con-
tainers. A 3-day dietary intake record was completed by study
participants at week 1, 4, 8 and 12. Nutritionist IV software (First
Databank, San Bruno, CA), adopted for Iranian food pattern, was
applied to determine participants' macro- and micro-nutrient in-
takes. The same nutritionist also measured anthropometric pa-
rameters (Seca, Hamburg, Germany) at the beginning and end of
the intervention in cardiology clinic.Please cite this article in press as: Raygan F, et al., The effects of probiotic
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The homeostasis model of assessment-insulin resistance
(HOMA-IR) was considered as the primary outcome, but in-
dicators of mental health and other metabolic parameters were
considered as secondary results. Fasting blood (10 mL) were taken
at baseline and after the 12-week intervention. ELISA kits were
used to determine insulin (DiaMetra, Milano, Italy) and high
sensitivity C-reactive protein (hs-CRP) (LDN, Nordhorn, Ger-
many). HOMA-IR and the quantitative insulin sensitivity check
index (QUICKI) were assessed in accordance with the standard
formulas. Enzymatic kits (Pars Azmun, Tehran, Iran) were applied
to estimate fasting plasma glucose (FPG) and lipid proﬁles. Nitric
oxide (NO) [12], total antioxidant capacity (TAC) [13], total
glutathione (GSH) [14] and malondialdehyde (MDA) levels [15]
were determined by the spectrophotometric test. Inter-assay
and intra-assay coefﬁcient variances (CVs) of metabolic proﬁles
were lower than 7%
2.4. Clinical assessment
Beck Depression Inventory (BDI) and Beck Anxiety Inventory
(BAI) developed by Beck et al. were assessed. Quality of sleep was
determined using Pittsburgh Sleep Quality Index (PSQI).
2.5. Statistical methods and sample size
Sample size formula for randomized clinical trial were used,
where type one (a) and type two errors (b) were 0.05, and 0.20
(power ¼ 80%), respectively. In a previous study [16], 1.61 as the SD
and 2.30 as the change in mean (d) of HOMA-IR were used. Ac-
cording to the formula, in each group 25 individuals were required;
after the attrition rate 20% in every group, the sample size was 30
persons in each group.
The KolmogoroveSmirnov test was used for checking the
normality of data. Differences in anthropometric measures and
dietary intakes between the two groups were tested using the
independent-samples t-test. To evaluate treatment impacts on
study variables, we used multiple linear regression models. Dif-
ferences in proportions were evaluated by Chi square test. Statis-
tical signiﬁcance was set at P-value <0.05. The Statistical Package
for Social Science version 18 (SPSS Inc., Chicago, Illinois, USA) was
used for statistical analyses of this trial.
3. Results
Three subjects in the supplements (n ¼ 3) and placebo (n ¼ 3)
groups dropped out for personal reasons (Fig.1). Finally, 54 patients
[selenium plus probiotic (n¼ 27) and placebo (n¼ 27)] ﬁnished the
trial. Overall, the compliance rate was high, such that more than
90% of capsules were consumed throughout the study in both
groups. No adverse effects were recorded in diabetic patients with
CHD after the intake of selenium and probiotic.
No difference in mean age, anthropometric parameters and
METs was seen between the two groups (Table 1).
We observed no signiﬁcant changes in dietary intake of macro-
and micronutrients between the two groups (Data not shown).
Probiotic and selenium co-supplementation decreased BDI
(b 1.46; 95% CI, 2.61, 0.31; P ¼ 0.01) and BAI (b 1.23; 95%
CI, 2.33, 0.12; P ¼ 0.02) compared with the placebo (Table 2).
Consuming probiotic plus selenium lowered FPG (b 10.80 mg/dL;
95% CI, 17.68, 3.92; P ¼ 0.003), insulin levels (b 3.42 mIU/mL;
95% CI, 4.93, 1.90; P < 0.001), HOMA-IR (b 0.96; 95%
CI, 1.45, 0.47; P < 0.001), and enhanced QUICKI (b 0.01; 95% CI,
0.007, 0.01; P < 0.001) compared with the placebo. Additionally, co-and selenium co-supplementation on mental health parameters and
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Fig. 1. Summary of patient ﬂow diagram.
Table 1
General characteristics of study participants.
Placebo group
(n ¼ 27)
Probiotic plus
selenium group
(n ¼ 27)
Pa
Age (y) 62.4 ± 13.1 64.8 ± 8.3 0.45
Gender
Female 17 (63.0) 16 (59.3) 0.78b
Male 10 (37.0) 11 (40.7)
Height (m) 160.7 ± 8.8 158.9 ± 10.4 0.46
Weight at study baseline (kg) 77.1 ± 13.1 78.7 ± 12.7 0.65
Weight at end-of-trial (kg) 77.3 ± 13.0 78.7 ± 12.7 0.68
Body weight change (kg) 0.2 ± 1.3 0.1 ± 0.6 0.61
BMI at study baseline (kg/m2) 29.9 ± 5.0 31.4 ± 5.8 0.31
BMI at end-of-trial (kg/m2) 30.0 ± 5.0 31.4 ± 5.7 0.33
BMI change (kg/m2) 0.1 ± 0.5 0.02 ± 0.3 0.56
Data are means± SDs.
BMI, body mass index.
a Obtained from independent samples t-test.
b Obtained from Pearson Chi-square test.
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CI, 56.18, 12.72; P ¼ 0.003), VLDL- (b 6.89 mg/dL; 95%
CI,11.23,2.54; P¼ 0.003), total cholesterol (b18.13mg/dL; 95%
CI, 23.42, 2.83; P ¼ 0.02) and hs-CRP (b 1043.28 ng/mL; 95%
CI, 1929.67, 156.89; P ¼ 0.02), and increased NO (b 7.86 mmol/L;
95% CI, 5.63, 10.09; P < 0.001), TAC (b 119.30 mmol/L; 95% CI, 63.04,
175.57; P < 0.001) and GSH (b 154.16 mmol/L; 95% CI, 82.57, 225.74;
P < 0.001) compared with the placebo. Probiotic and selenium co-
supplementation did not affect PSQI, other metabolic proﬁles and
blood pressures.
4. Discussion
We found that co-supplementationwith probiotic and selenium
to diabetic people with CHD improved indicators of mental health
and metabolic proﬁles.Please cite this article in press as: Raygan F, et al., The effects of probiotic
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We demonstrated that consuming probiotic plus selenium by
diabetic people with CHD signiﬁcantly improved BDI and BAI
scores, but did not affect PSQI. Intervention studies of selenium
administration in humans and its effects on depression have pro-
posed inconsistent ﬁndings. In a study by Mokhber et al. [17],
100 mg/day selenium administration for 2 months to pregnant
women prevented postpartum depression. Moreover, probiotic
administration for 12 weeks to people with multiple sclerosis
improved mental health parameters [18]. Selenium intake may
affect mental health parameters through modulating thyroid
function, which in turn play a role in the reduction of depression
[19]. The mainmechanisms by which probiotic intake may improve
metal health symptoms include the modulation of neurotrans-
mitters and inﬂammation [20].
4.2. Effect on metabolic parameters
In a study by Wang et al. [21], higher dietary selenium intake
signiﬁcantly reduced insulin resistance. We have previously showed
that 200 mg/day selenium intake for 2 months to women with poly-
cystic ovary syndrome improved insulin resistance, triglycerides and
VLDL-cholesterol levels, while did not affect other metabolic proﬁles
[22]. Insulin resistance and dyslipidemia lead to peripheral arterial
disorder and endothelial cell dysfunctions, thus increasing risk fac-
tors for heart failure [23]. Selenium intake may improve glycemic
status and lipid proﬁles through enhancing gene expression of very
long chain dehydrogenase and enzymes related to b-oxidation [24].
In addition, probiotic intake by increasing b-oxidation of long-chain
fatty acids in liver and muscle tissues and decreasing lipid synthesis
in liver may decrease insulin resistance and dyslipidemia [25].
4.3. Effect on inﬂammation and oxidative stress
This study documented that taking probiotic plus selenium
decreased hs-CRP, and increased NO, TAC and GSH levels, but didand selenium co-supplementation on mental health parameters and
ase: A randomized, double-blind, placebo-controlled trial, Clinical
Table 2
The effect of probiotic and selenium co-supplementation onmental health parameters, cardio-metabolic risk and biomarkers of oxidative stress in type 2 diabetic patients with
coronary heart disease.
Variables Placebo group (n ¼ 27) Probiotic plus selenium group
(n ¼ 27)
Difference in outcome measures between probiotic plus
selenium and placebo treatment groupsa
Baseline Week 12 Baseline Week 12 b (95% CI) Pb
BDI 24.5 ± 4.1 23.5 ± 3.6 24.9 ± 4.5 22.2 ± 3.8 1.46 (2.61, 0.31) 0.01
BAI 17.9 ± 4.5 16.8 ± 4.7 18.1 ± 4.8 15.7 ± 4.3 1.23 (2.33, 0.12) 0.02
PSQI 8.2 ± 1.9 8.3 ± 2.2 7.9 ± 1.8 7.7 ± 2.1 0.47 (1.56, 0.61) 0.38
FPG (mg/dL) 134.7 ± 43.9 132.6 ± 43.1 142.0 ± 41.9 129.5 ± 45.5 10.80 (17.68, 3.92) 0.003
Insulin (mIU/mL) 11.5 ± 4.8 12.7 ± 4.9 12.9 ± 2.5 10.3 ± 2.7 3.42 (4.93, 1.90) <0.001
HOMA-IR 3.8 ± 2.1 4.1 ± 1.9 4.5 ± 1.4 3.6 ± 1.4 0.96 (1.45, 0.47) <0.001
QUICKI 0.32 ± 0.02 0.31 ± 0.01 0.30 ± 0.01 0.32 ± 0.01 0.01 (0.007, 0.01) <0.001
Triglycerides (mg/dL) 179.9 ± 68.2 179.1 ± 67.9 176.8 ± 76.4 143.7 ± 62.8 34.45 (56.18, 12.72) 0.003
VLDL-cholesterol (mg/dL) 36.0 ± 13.6 35.8 ± 13.6 35.3 ± 15.3 28.7 ± 12.6 6.89 (11.23, 2.54) 0.003
Total cholesterol (mg/dL) 171.6 ± 41.4 174.9 ± 49.3 169.6 ± 29.8 154.6 ± 24.3 18.13 (23.42, 2.83) 0.02
LDL-cholesterol (mg/dL) 90.0 ± 42.7 91.9 ± 50.5 87.5 ± 24.5 79.7 ± 17.6 8.69 (22.09, 4.70) 0.19
HDL-cholesterol (mg/dL) 45.7 ± 8.3 47.3 ± 8.7 46.7 ± 10.7 46.2 ± 9.4 2.22 (5.20, 0.75) 0.14
Total-/HDL-cholesterol ratio 3.8 ± 1.0 3.8 ± 1.4 3.8 ± 0.9 3.4 ± 0.6 1.48 (0.68, 0.12) 0.17
hs-CRP (ng/mL) 2683.9 ± 1812.5 3321.6 ± 2667.4 2618.5 ± 1395.9 2133.3 ± 1127.6 1043.28 (1929.67, 156.89) 0.02
NO (mmol/L) 36.0 ± 8.7 35.4 ± 8.3 36.6 ± 5.7 43.6 ± 6.1 7.86 (5.63, 10.09) <0.001
TAC (mmol/L) 959.6 ± 204.7 944.5 ± 194.0 1062.2 ± 98.3 1141.8 ± 102.9 119.30 (63.04, 175.57) <0.001
GSH (mmol/L) 511.7 ± 117.7 491.9 ± 167.8 542.3 ± 73.9 669.5 ± 149.9 154.16 (82.57, 225.74) <0.001
MDA (mmol/L) 2.4 ± 0.4 2.5 ± 0.4 2.7 ± 0.3 2.7 ± 0.2 0.10 (0.04, 0.25) 0.17
SBP (mmHg) 136.7 ± 9.3 135.9 ± 7.6 134.2 ± 12.6 132.4 ± 9.6 2.64 (6.32, 1.02) 0.15
DBP (mmHg) 78.2 ± 5.1 78.5 ± 5.7 76.8 ± 6.1 77.5 ± 6.8 0.11 (2.54, 2.77) 0.93
Data are mean ±SDs.
BDI, beck depression inventory; BAI, beck anxiety inventory; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model
of assessment-estimated insulin resistance; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; PSQI, Pittsburgh Sleep Quality Index;
QUICKI, quantitative insulin sensitivity check index; SBP, systolic blood pressure; TAC, total antioxidant capacity.
a “Outcome measures” refers to the change in values of measures of interest between baseline and week 12. b [difference in the mean outcomes measures between
treatment groups (probiotic plus selenium group ¼ 1 and placebo group ¼ 0)].
b Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age and baseline BMI).
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intake for 42 days in an animal model signiﬁcantly decreased bio-
markers of oxidative stress [26]. Probiotic supplementation for 8
weeks to people with rheumatoid arthritis also decreased inﬂam-
matory cytokines [27]. Tissue inﬂammation and oxidative damage
are main pathogenic factors for the progress of diabetic complica-
tions [28]. Therefore, selenium and probiotic intake due to their
anti-inﬂammatory and antioxidative effects may reduce compli-
cations related to diabetes and CHD events. The anti-inﬂammatory
and antioxidative effects of selenium may be due to blocking acti-
vation of nuclear factor-kB through modulating selenoprotein
genes expression and inhibiting production of reactive oxygen
species [29]. Moreover, probiotic may reduce inﬂammatory factors
and oxidative damage through producing short chain fatty acids in
the gut and the decreasing production of free radicals [30].
Our study had a number of limitations. We did not measure
plasma and/or urine selenium levels and fecal bacteria loads.
Moreover, we did not determine the effects of selenium and pro-
biotic co-supplementation on gene expression related to metabolic
status.
Overall, probiotic and selenium co-supplementation to diabetic
people with CHD had beneﬁcial effects on indicators of mental
health and metabolic proﬁles.
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